We suspect that the proportion of patients who are non-responders to BRAF inhibitor treatment contain patients with melanoma metastases that do not share the same BRAF status, wherein beside the BRAF mutated metastases further tumour spots with BRAF wild-type are present. Here, BRAF is linked to neoplasm.